KUALA LUMPUR: UOB Kay Hian Malaysia Research is looking past Duopharma Biotech’s FY20 performance towards next year as its niche drug facilities will enable it to manufacture a wider range of high value prescription generic drugs.
The research house had on Tuesday said the wider range of drugs would be via Duopharma’s strategic partnerships while the facilities would be ready by end of next year.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!